中山醫學大學機構典藏 CSMUIR:Item 310902500/25039
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17918/22933 (78%)
造访人次 : 7429911      在线人数 : 55
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/25039


    题名: Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics
    作者: Chiu, YM;Chen, DY
    关键词: Infection risk;treatment;non-biologics;biologics;inflammatory arthritis
    日期: 2020
    上传时间: 2022-08-09T09:27:27Z (UTC)
    出版者: TAYLOR & FRANCIS LTD
    ISSN: 1744-666X
    摘要: Introduction: Despite the therapeutic effectiveness of biologics targeting immune cells or cytokines in patients with inflammatory arthritis, which reflects their pathogenic roles, an increased infection risk is observed in those undergoing biological treatment. However, there are limited data regarding the comparison of infection risks in inflammatory arthritis patients treated with non-biologics (csDMARDs), biologics (bDMARDs), including tumor necrosis factor (TNF) inhibitors and non-TNF inhibitors, or targeted synthetic (ts)DMARDs. Areas covered: Through a review of English-language literature as of 30 June 2019, we focus on the existing evidence on the risk of infections caused by bacteria, Mycobacterium tuberculosis, and hepatitis virus in inflammatory arthritis patients undergoing treatment with csDMARDs, bDMARDs, or tsDMARDs. Expert opinion: While the risks of bacterial and mycobacterial infection are increased in arthritis patients treated with csDMARDs, the risks are further higher in those receiving bDMARDs therapy, particularly TNF inhibitors. Regarding HBV infection, antiviral therapy may effectively prevent HBV reactivation in patients receiving bDMARDs, especially rituximab. However, more data are needed to establish effective preventive strategies for HBsAg-negative/HBcAb-positive patients. It seems safe to use cyclosporine and TNF inhibitors in patients with HCV infection, while those undergoing rituximab therapies should be frequently monitored for HCV activity.
    URI: http://dx.doi.org/10.1080/1744666X.2019.1705785
    https://www.webofscience.com/wos/woscc/full-record/WOS:000506555200001
    https://ir.csmu.edu.tw:8080/handle/310902500/25039
    關聯: EXPERT REVIEW OF CLINICAL IMMUNOLOGY ,2020 ,v16 ,issue 2 ,p207-228
    显示于类别:[中山醫學大學研究成果] 其他文獻

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML192检视/开启


    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈